Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,482 Cr revenue.
COGS 38.5%, employees 14.7%.
“revenues of INR $13.”
“are expecting a very meaningful improvement in the Q4 performance.”
“Q4 is tracking towards a meaningful improvement in performance supported by ongoing project deliveries.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 13.7%▲ | 10.5% |
| ROCE | 18.2%▲ | 13.8% |
| Net Margin | 10.7%▲ | 8.7% |
| EBITDA Margin | 21.6%▲ | 16.0% |
| Debt To Equity | 0.41x▲ | 0.21x |
| Rev Growth 3yr | 5.9%▲ | 5.8% |
| EPS Growth 3yr | 7.5%▲ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹5,092 Cr +13.6% | ₹4,482 Cr -0.5% | ₹4,506 Cr -0.1% | ₹4,512 Cr +19.8% | ₹3,765 Cr +16.3% | ₹3,238 Cr +24.6% | ₹2,599 Cr +14.0% | ₹2,279 Cr |
| Other Income | ₹13 Cr +4.3% | ₹13 Cr +193.5% | ₹4 Cr -68.1% | ₹14 Cr -21.7% | ₹18 Cr -34.5% | ₹27 Cr -26.5% | ₹37 Cr +37.0% | ₹27 Cr |
| Total Income | ₹5,106 Cr +13.6% | ₹4,495 Cr -0.4% | ₹4,511 Cr -0.3% | ₹4,526 Cr +19.6% | ₹3,783 Cr +15.9% | ₹3,264 Cr +23.9% | ₹2,635 Cr +14.3% | ₹2,306 Cr |
| COGS | ₹1,810 Cr +4.9% | ₹1,726 Cr -14.6% | ₹2,021 Cr -12.4% | ₹2,307 Cr +22.5% | ₹1,884 Cr +35.4% | ₹1,391 Cr +8.6% | ₹1,281 Cr +2.0% | ₹1,256 Cr |
| ₹4,391 Cr +13.6% | ₹3,865 Cr -2.5% | ₹3,964 Cr +3.3% | ₹3,839 Cr +19.0% | ₹3,225 Cr +26.0% | ₹2,560 Cr +14.4% | ₹2,237 Cr +10.3% | ₹2,029 Cr | |
| Profit Before Tax | ₹720 Cr +9.1% | ₹660 Cr +20.6% | ₹547 Cr -20.4% | ₹687 Cr +23.1% | ₹558 Cr -20.8% | ₹704 Cr +65.5% | ₹426 Cr +53.8% | ₹277 Cr |
| Exceptional Items | ₹5 Cr -84.3% | ₹31 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹28 Cr | ₹0.00 Cr |
| ₹175 Cr +10.1% | ₹159 Cr +11.8% | ₹142 Cr -16.8% | ₹171 Cr +17.4% | ₹145 Cr -6.2% | ₹155 Cr +33.9% | ₹116 Cr +29.9% | ₹89 Cr | |
| Net Profit | ₹545 Cr +8.8% | ₹502 Cr +23.7% | ₹405 Cr -21.5% | ₹517 Cr +25.2% | ₹413 Cr -24.9% | ₹549 Cr +63.8% | ₹335 Cr +41.9% | ₹236 Cr |
| Profit (Owners) | ₹545 Cr +8.8% | ₹502 Cr +23.7% | ₹405 Cr -21.5% | ₹517 Cr +25.2% | ₹413 Cr -24.9% | ₹549 Cr +63.8% | ₹335 Cr +41.9% | ₹236 Cr |
| Other Comprehensive Income | ₹88 Cr +224.4% | ₹27 Cr +31.8% | ₹21 Cr -64.0% | ₹57 Cr +42.0% | ₹40 Cr ↑ Recovery | (₹26 Cr) ↓ Decline | ₹2 Cr -83.2% | ₹13 Cr |
| EPS | ₹22.48 | ₹20.68 | ₹16.72 | ₹21.34 | ₹16.64 | ₹22.18 | ₹13.19 | ₹9.30 |
| Diluted Shares | ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Granules India Limited has informed the Exchange about Schedule of meet
Granules India Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility".
Granules India Limited has informed the Exchange about Schedule of meet
Significant increase in volume has been observed in Granules India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market ...
Granules India Limited has informed the Exchange about Transcript
Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Granules India Limited has informed the Exchange that Record date for the purpose of Dividend is 30-Jul-2026.
Monitoring Agency Report for the Quarter ended on March 31, 2026.
Granules India Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "Press Release".
Granules India Limited has informed the Exchange about Presentation
Granules India Limited has informed the Exchange about change in Management
Granules India Limited has informed the Exchange regarding Outcome of Board Meeting held on April 29, 2026.
Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Granules India Limited has informed the Exchange about Schedule of meet
Granules India Limited has informed the Exchange regarding a press release dated March 31, 2026, titled "Granules Life Sciences Receives VAI Classification following US FDA Inspection".